Valeant Pharmaceuticals International Inc (VRX)

9.27
0.25 2.80
NYSE : Health Care
Prev Close 9.02
Open 9.12
Day Low/High 9.01 / 9.56
52 Wk Low/High 8.31 / 38.50
Volume 16.67M
Avg Volume 19.11M
Exchange NYSE
Shares Outstanding 347.85M
Market Cap 3.14B
EPS -6.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Vive la U.S. Earnings: Cramer's 'Mad Money' Recap (Monday 4/24/17)

Vive la U.S. Earnings: Cramer's 'Mad Money' Recap (Monday 4/24/17)

Jim Cramer says a rally on French election results is fine, but don't forget great U.S. corporate earnings and merger activity.

10 Things We Learned From Our Daily Facebook Show With Jim Cramer

10 Things We Learned From Our Daily Facebook Show With Jim Cramer

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer breaks down the day's trending stocks on our daily Facebook Live show, which airs weekdays at 10 a.m. EST.

Valeant Shares Plummet as Debt Issues Remain Unsolved, Prices New Psoriasis Drug

Valeant Shares Plummet as Debt Issues Remain Unsolved, Prices New Psoriasis Drug

The drugmaker's stock fell after Wells Fargo lowered its price target range.

Jim Cramer on Valeant Pharmaceuticals: The Debt Is Humongous

Jim Cramer on Valeant Pharmaceuticals: The Debt Is Humongous

TheStreet's Jim Cramer said Valeant Pharmaceuticals' debt load is humongous.

Jim Cramer -- Valeant's Not Worth the Speculation

Jim Cramer -- Valeant's Not Worth the Speculation

Valeant's debt load is massive and buying the stock is a risky bet, Cramer said.

Jim Cramer on GE, Schlumberger, Honeywell, Visa, Facebook, Valeant and Arconic

Jim Cramer on GE, Schlumberger, Honeywell, Visa, Facebook, Valeant and Arconic

TheStreet's Jim Cramer discusses Friday's trending stocks including General Electric, Schlumberger, Honeywell, Visa, Facebook, Valeant Pharmaceuticals and Arconic.

Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger

Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger

Alpine Immune Sciences, a cancer immunotherapy company founded by former Dendreon CEO Mitch Gold, is listing publicly through a merger with Nivalis Therapeutics.

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Apple, Allergan and Western Digital.

Takeaways and Observations; Play a Tesla Tune: Doug Kass' Views

Takeaways and Observations; Play a Tesla Tune: Doug Kass' Views

Doug Kass shares his thoughts on Tesla and the second quarter.

Home Depot, Federal Realty, more: 'Mad Money' Lightning Round

Home Depot, Federal Realty, more: 'Mad Money' Lightning Round

Jim Cramer is bullish on Home Depot, Corbus Pharmaceuticals, Federal Realty and Vector Group.

Market Stays Strong in the Fight: Cramer's 'Mad Money' Recap (Friday 4/7/17)

Market Stays Strong in the Fight: Cramer's 'Mad Money' Recap (Friday 4/7/17)

Even with a trifecta of worries, stocks hold tight thanks to decisive U.S. action in Syria, says Jim Cramer.

Valeant Shares on Pace to Finish Week at Lowest Level Since 2008

Valeant Shares on Pace to Finish Week at Lowest Level Since 2008

Can the drugmaker bounce back?

Valeant Shares Close Below $10 for First Time Since 2008

Valeant Shares Close Below $10 for First Time Since 2008

Can the drugmaker bounce back?

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

Valeant Plummets After Revealing Jaw-Dropping Payday for Its CEO

Valeant Plummets After Revealing Jaw-Dropping Payday for Its CEO

Investors are ticked off about the CEO's bonanza amid dismal results.

Valeant Pharmaceuticals Still Searches for a Bottom

Valeant Pharmaceuticals Still Searches for a Bottom

The stock could have a meaningful bounce in this downtrend, but it is unlikely to reverse things overnight.

After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite

After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite

The animal health company combines with its former owner in a reverse merger.

Astrazeneca Scores Milestone Victory in Oncology

Astrazeneca Scores Milestone Victory in Oncology

A double victory in oncology failed to lift Astra stock, amid broad weakness in European markets

Cenovus Falls After Conoco Deal, Valeant Resumes Decline: Most Active Stocks, March 30

Cenovus Falls After Conoco Deal, Valeant Resumes Decline: Most Active Stocks, March 30

Cenovus Energy was one of the biggest losers after the company agreed to purchase properties ConocoPhillips divested.

Ackman Reflects on His Valeant Investment

Ackman Reflects on His Valeant Investment

The Pershing Square manager also holds a stake in Chipotle and used to be invested in JCPenney and Canadian Pacific Railway. Here are some of his most contentious investments.

Dow Climbs on Financials' Rebound as Nasdaq Hits New Record Close

Dow Climbs on Financials' Rebound as Nasdaq Hits New Record Close

The Dow Jones Industrial Average shakes off recent weakness to post modest gains as financial stocks stage a slight rebound.

Dow Leads Wall Street as Financials Stocks Stage a Small Rebound

Dow Leads Wall Street as Financials Stocks Stage a Small Rebound

The Dow Jones Industrial Average shakes off recent weakness to post modest gains as a financials stocks stage a slight rebound.

Midday Report: Ackman Says Sorry for Valeant Stake; Financials Climb

Midday Report: Ackman Says Sorry for Valeant Stake; Financials Climb

Stocks held onto modest gains through the morning as the financial sector set up a rebound.

U.S. Stocks Climb to Session Highs as Financials Make a Rebound

U.S. Stocks Climb to Session Highs as Financials Make a Rebound

Stocks add to earlier gains Thursday as the financial sector makes a slight rebound after recent weakness.

Ackman Says He's Sorry For Valeant Investment

Ackman Says He's Sorry For Valeant Investment

The Pershing Square manager apologized to clients in his annual letter.